HIV cure and eradication: How will we get from the laboratory to effective clinical trials?

AIDS

Volumn 25, Issue 7, 2011, Pages 885-897

  Lewin, Sharon R ^a,b,c   Rouzioux, Christine ^d,e  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c BURNET INSTITUTE   (Australia)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Eradication; HIV; latency; reservoirs

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 7; PROSTRATIN; UNCLASSIFIED DRUG;

CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; ERADICATION THERAPY; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY; LATENT VIRUS INFECTION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW;

ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RECEPTORS, CCR5;

EID: 79954664166     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283467041     Document Type: Review

References (130)

1. Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, Chun TW, et al. HIVpersistenceand theprospectof long-term drug-free remissions for HIV-infected individuals. Science 2010; 329:174-180.
2. Richman DD, Margolis DM, DelaneyM, GreeneWC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
3. Josefsson L, Dahl V, PalmerS. Can HIVinfection beeradicated through use of potent antiviral agents? Curr Opin Infect Dis 2010; 23:628-632.
4. Choudhary SK, Margolis DM. Curing HIV: pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol 2011; 51:397-418.
5. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. Understanding HIV-1 latency provides clues for the eradica-tion of long-term reservoirs. Nat Rev Microbiol 2009; 7:798-812.
6. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al. HIV-infectedadultswithaCD4cell countgreaterthan 500cells/mm3 on long-term combination antiretroviral ther-apy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72-77. (Pubitemid 47514615)
7. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95. (Pubitemid 351640011)
8. ART-CC. Life expectancy of individuals on combination anti-retroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
9. Neuhaus J, Angus B, Kowalska JD, La Rosa A, Sampson J, Wentworth D, et al. Riskof all-causemortality associatedwith nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 2010; 24:697-706.
10. Deeks SG, Phillips AN. HIV infection, antiretroviral treat-ment, ageing, and non-AIDS related morbidity. BMJ 2009; 338:a3172.
11. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
12. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adultswith HIV infection.JInfectDis 2010; 201:1788-1795.
13. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-1193 (Pubitemid 36667761)
14. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: WHO; 2010.
15. DHHS. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2009.
16. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360: 692-698.
17. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, et al. Evidence for the cure of HIV infection by CCR5{Delta}32/{Delta}32 stem cell transplantation. Blood 2010; 8:8.
18. Descours B, Avettand-Fenoël V, Blanc C, Samri A, Mélard A, Prazuck T, et al. Transitional and central memory CD4 T cells are highly infected in long term non progressors and elite controllers. Retrovirology 2009; 6(Suppl 3) (published online October 22, 2009).
19. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007; 27:406-416. (Pubitemid 47418678)
20. Dalmasso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, ChaixML, et al. Distinctgenetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. Plos One 2008; 3:e3907.
21. Avettand-Fenoel V, Prazuck T, Hocqueloux L, Melard A, Michau C, Kerdraon R, et al. HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term nonprogressors. AIDS 2008; 22:1880-1882.
22. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of ther-apy. J Infect Dis 2008; 197:126-133. (Pubitemid 351263476)
23. Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, Hunt PW, et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 2009; 83:329-335.
24. Pereyra F, Palmer S, Miura T, Block BL, Wiegand A, Rothchild AC, et al. Persistent low-level viremia in HIV-1 elite control-lers and relationship to immunologic parameters. J Infect Dis 2009; 200:984-990.
25. Saez-Cirion A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C, et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol 2009; 182:7828-7837.
26. Study TIHC. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 4:4.
27. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-genome association study of major deter-minants for host control of HIV-1. Science 2007; 317:944-947. (Pubitemid 47301321)
28. Hersperger AR, Martin JN, Shin LY, Sheth PM, Kovacs CM, Cosma GL, et al. Increased HIV-specific CD8+ T-cell cyto-toxic potential in HIVelite controllers is associated with T-bet expression. Blood 2011. [Epub ahead of print]
29. Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, Shin LY, et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 2010; 6:e1000917.
30. Williams LD, Bansal A, Sabbaj S, Heath SL, Song W, Tang J, et al. Interleukin-21-producing HIV-1-specificCD8Tcellsare preferentially seen in elite controllers. J Virol 2011; 85:2316-2324.
31. Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, Garcia JC, et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009; 113:3978-3989.
32. Ferre AL, Lemongello D, Hunt PW, Morris MM, Garcia JC, Pollard RB, et al. Immunodominant HIV-specificCD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosaof HIV controllers. J Virol 2010; 84:10354-10365.
33. HuangJ, Burke PS, Cung TD, Pereyra F, Toth I, Walker BD, et al. Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendriticcells in HIV-1-infectedelitecontrollers.J Virol2010; 84:9463-9471.
34. BrummeZL, Li C, Miura T, SelaJ, Rosato PC, BrummeCJ, et al. Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers. J Acquir Immune Defic Syndr 2011; 56:100-108.
35. MiuraT, BrummeZL, Brockman MA, Rosato P, SelaJ, Brumme CJ, et al. Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol 2010; 84:7581-7591.
36. Miura T, Brockman MA, Brumme ZL, Brumme CJ, Pereyra F, Trocha A, et al. HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J Virol 2009; 83:140-149.
37. Madec Y, Boufassa F, Avettand-Fenoel V, Hendou S, Melard A, Boucherit S, et al. Early control of HIV-1 infection in long-term nonprogressors followed since diagnosis in the ANRS SEROCO/HEMOCO cohort. J Acquir Immune Defic Syndr 2009; 50:19-26.
38. Julg B, Pereyra F, Buzon MJ, Piechocka-Trocha A, Clark MJ, Baker BM, et al. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis 2010; 51:233-238.
39. Graf EH, Mexas AM, Yu JJ, Shaheen F, Liszewski MK, Di Mascio M, et al. Elite suppressors harbor low levels of inte-grated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog 2011; 7:e1001300.
40. O'Connell KA, Brennan TP, Bailey JR, Ray SC, Siliciano RF, Blankson JN. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol 2010; 84:7018-7028.
41. Zack JA, Haislip AM, Krogstad P, Chen IS. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol 1992; 66:1717-1725.
42. Finzi D, Blankson J, Siliciano J, Margolick J, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-517. (Pubitemid 29220209)
43. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
44. Finzi D, Hermankova M, Pierson T, Carruth L, BuckC, Chais-son R, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300. (Pubitemid 27495742)
45. DaiJ, Agosto LM, BaytopC, YuJJ, PaceMJ, Liszewski MK, et al. Human immunodeficiency virus integrates directly into naive resting CD4+ T cells but enters naive cells less efficiently than memory cells. J Virol 2009; 83:4528-4537.
46. Wightman F, Solomon A, Khoury G, Green J, Gray L, Gorry P, et al. Both CD31-positive and CD31-negative naive CD4 T-cells are persistent HIV-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis 2010; 202: 1738-1748.
47. CarterCC, Onafuwa-Nuga A, McNamara LA, Riddell Jt, Bixby D, Savona MR, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reser-voirs. Nat Med 2010; 16:446-451.
48. Brooks DG, Kitchen SG, Kitchen CM, Scripture-Adams DD, Zack JA. Generation of HIV latency during thymopoiesis. Nat Med 2001; 7:459-464. (Pubitemid 32298549)
49. Gorry P, Purcell D, Howard J, McPhee D. Restricted HIV-1 infection of human astrocytes: potential role of nef in the regulation of virus replication. J Neurovirol 1998; 4:377-386. (Pubitemid 28395718)
50. Churchill MJ, Gorry PR, Cowley D, Lal L, Sonza S, Purcell DF, et al. Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol 2006; 12:146-152. (Pubitemid 44574605)
51. Ellery PJ, Tippett E, Chiu Y-L, Paukovics G, Cameron PU, Solomon A, et al. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol 2007; 178:6581-6589. (Pubitemid 46717442)
52. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008; 197:714-720. (Pubitemid 351364472)
53. Sheth PM, Kovacs C, Kemal KS, Jones RB, RaboudJM, Pilon R, et al. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS 2009; 23:2050-2054.
54. Petito CK. Human immunodeficiency virus type 1 compart-mentalization in the central nervous system. J Neurovirol 2004; 10 (Suppl 1):21-24. (Pubitemid 38325089)
55. Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J, Mullins JI, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: impli-cations for eradication of virus. J Infect Dis 2007; 195:1762-1764. (Pubitemid 46870248)
56. Sonza S, Maerz A, Deacon N, Meanger J, Mills J, Crowe S. Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly iso-lated peripheral blood monocytes. J Virol 1996; 70:3863-3869. (Pubitemid 26157366)
57. O'Doherty U, Swiggard WJ, Jeyakumar D, McGain D, Malim MH. A sensitive, quantitative assay for human immuno-deficiency virus type 1 integration. J Virol 2002; 76:10942-10950. (Pubitemid 35176211)
58. Lewin SR, MurrayJM, Solomon A, Wightman F, Cameron PU, Purcell DJ, et al. Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection. J Acquir Immune Defic Syndr 2008; 47:140-147. (Pubitemid 351172180)
59. Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral ther-apy. Nat Med 2000; 6:76-81. (Pubitemid 30048530)
60. Sharkey M, Triques K, Kuritzkes DR, Stevenson M. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol 2005; 79:5203-5210. (Pubitemid 40464268)
61. PalmerS, Wiegand AP, Maldarelli F, Bazmi H, MicanJM, Polis M, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodefi-ciency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531-4536. (Pubitemid 37259753)
62. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc NatlAcad Sci USA 2008; 105:3879-3884. (Pubitemid 351723493)
63. Brennan TP, Woods JO, Sedaghat AR, Siliciano JD, Siliciano RF, Wilke CO. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 2009; 83:8470-8481.
64. Sedaghat AR, Siliciano JD, Brennan TP, Wilke CO, Siliciano RF. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog 2007; 3:e122.
65. Lewin S, Vesanen M, Kostrikis L, Hurley A, Duran M, Zhang L, et al. The use of real-time PCR and molecular beacons to detectvirus-replication in HIV-1-infected individuals on pro-longed effective antiretroviral therapy. J Virol 1999; 73:6099-6103. (Pubitemid 29274900)
66. Schmid A, Gianella S, von Wyl V, Metzner KJ, Scherrer AU, Niederost B, et al. Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. Plos One 2010; 5:e13310.
67. Pasternak AO, Jurriaans S, Bakker M, Prins JM, Berkhout B, Lukashov VV. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetect-able plasma viremia predict the therapy outcome. Plos One 2009; 4:e8490.
68. Vesanen M, Markowitz M, Cao Y, Ho DD, Saksela K. Human immunodeficiency virus type-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells. Virology 1997; 236:104-109. (Pubitemid 27410357)
69. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretro-viral therapy. J Infect Dis 2010; 202:1553-1561.
70. North TW, Higgins J, Deere JD, Hayes TL, Villalobos A, Adamson L, et al. Viral sanctuaries during highly active anti-retroviral therapy in a nonhuman primate model for AIDS. J Virol 2010; 84:2913-2922.
71. Avettand-Fenoel V, Chaix ML, Blanche S, Burgard M, Floch C, Toure K, et al. LTR real-time PCRfor HIV-1 DNAquantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol 2009; 81:217-223.
72. Bourry O, Mannioui A, Sellier P, Roucairol C, Durand-Gasselin L, Dereuddre-Bosquet N, et al. Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion. Retrovirology 2010; 7:78.
73. Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M. Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog 2011; 7:e1001303.
74. Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Gunthard HF, et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis 2008; 197:411-419. (Pubitemid 351263423)
75. Agosto LM, Liszewski MK, Mexas A, Graf E, PaceM, YuJJ, et al. Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs. Virology 2011; 409:46-53.
76. Lassen KG, Ramyar KX, Bailey JR, Zhou Y, Siliciano RF. Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog 2006; 2:e68.
77. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active anti-retroviral therapy. Proc Natl Acad Sci USA 2009; 106: 9403-9408.
78. McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patientswith HIV-1 suppression during receiptof combination antiretroviral ther-apy. Clin Infect Dis 2010; 50:912-919.
79. BuzonJM, Massanella M, Llibre JM, EsteveA, Dahl V, Puertas MC, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16:460-465.
80. Yukl SA, Shergill AK, McQuaid K, GianellaS, Lampiris H, Hare CB, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010; 24:2451-2460.
81. Gandhi RT, Bosch RJ, Aga E, Albrecht M, Demeter LM, Dykes C, et al. No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis 2010; 201: 293-296.
82. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7.
83. Yilmaz A, Verhofstede C, D'Avolio A, Watson V, Hagberg L, Fuchs D, et al. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on sup-pressive antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 16:16.
84. Carolina G, Diaz L, Hernández-Novoa B, Vallejo A, Page C, Lorente R, et al. Effect of the intensification with a CCR5 antagonist on the decay of the HIV-1 latent reservoir and residual viremia. In 17th Conference on Retroviruses and Opportunistic Infections. San Francisco; 2010.
85. Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, ViardJP, et al. Long-term immunovirologiccontrol following antiretroviral therapy interruption in patients trea-ted at the time of primary HIV-1 infection. AIDS 2010; 24:1598-1601.
86. Strain MC, LittleSJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, et al. Effect of treatment, during primary infection, on estab-lishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005; 191:1410-1418. (Pubitemid 40563351)
87. Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, Louie M, et al. Discontinuation of antiretroviral therapy com-menced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002; 186:634-643. (Pubitemid 34925535)
88. Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, Acheampong EA, et al. IL-7isapotentandproviral strain-specificinducerof latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115:128-137. (Pubitemid 40385513)
89. Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelievre JD, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119:997-1007.
90. Sereti I, Dunham RM, SpritzlerJ, Aga E, Proschan MA, Medvik K, et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009; 113:6304-6314.
91. Imamichi H, Degray G, Asmuth DM, Fischl MA, Landay AL, Lederman MM, et al. HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS 2011; 25:159-164.
92. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, Quivy V, et al. Synergistic activation of HIV-1 expression by deacety-lase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 2009; 4:e6093.
93. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366:549-555. (Pubitemid 41140329)
94. Archin NM, EronJJ, PalmerS, Hartmann-DuffA, MartinsonJA, Wiegand A, et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 2008; 22:1131-1135.
95. SilicianoJD, Lai J, Callender M, Pitt E, Zhang H, MargolickJB, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007; 195:833-836. (Pubitemid 46363928)
96. Sagot-Lerolle N, LamineA, ChaixML, Boufassa F, AboulkerJP, Costagliola D, et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 2008; 22:1125-1129.
97. ContrerasX, SchwenekerM, Chen CS, McCuneJM, DeeksSG, Martin J, et al. Suberoylanilide hydroxamic acid reactivates HIVfrom latently infected cells.J Biol Chem 2009; 284:6782-6789.
98. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009; 25:207-212.
99. BlazkovaJ, Trejbalova K, Gondois-Rey F, Halfon P, Philibert P, Guiguen A, et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog 2009; 5:e1000554.
100. Burnett JC, Lim KI, Calafi A, Rossi JJ, Schaffer DV, Arkin AP. Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol 2010; 84:5958-5974.
101. Fernandez G, Zeichner SL. Cell line-dependent variability in HIV activation by DNMT inhibitors. VirolJ 2010; 7:266.
102. Autran B, Murphy RL, Costagliola D, Tubiana R, Clotet B, Gatell J, et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 2008; 22: 1313-1322.
103. Kinloch-de Loes S, Hoen B, Smith DE, Autran B, Lampe FC, Phillips AN, et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005; 192:607-617. (Pubitemid 41099309)
104. Vagenas P, Aravantinou M, Williams VG, Jasny E, PiatakMJr, Lifson JD, et al. A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral ther-apy cessation. Plos One 2010; 5:e12891.
105. Holt N, WangJ, Kim K, Friedman G, Wang X, Taupin V, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010; 28:839-847.
106. Lalezari J, Mitsuyasu R, Deeks D, Wang S, Lee G, Holmes M, et al. Successful and persistent engraftment of ZFN-M-R5-D autologous CD4 T cells (SB-728-T) in aviremic HIV-infected subjects on HAART. In: 18th Conference on Retroviruses and Opportunistic Infections (CROI); Boston; 2011.
107. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010; 2:36ra43.
108. Ghosn J, Deveau C, Chaix ML, Goujard C, GalimandJ, Zitoun Y, et al. Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort. J Antimicrob Chemother 2010; 65:741-748.
109. RouziouxC, HubertJB, BurgardM, DeveauC, GoujardC, Bary M, et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 2005; 192:46-55.
110. Martinez V, Costagliola D, Bonduelle O, N'go N, Schnuriger A, Theodorou I, et al. Combination ofHIV-1-specificCD4Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis 2005; 191:2053-2063. (Pubitemid 40800576)
111. Bloch MT, Smith DE, Quan D, Kaldor JM, Zaunders JJ, Petoumenos K, et al. The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomizedclinical trial (Pulse).J Acquir Immune Defic Syndr 2006; 42:192-202. (Pubitemid 43884714)
112. Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, et al. Rebound of plasma viremia following cessa-tion of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 2010; 24:2803-2808.
113. Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 2009; 23:1799-1806.
114. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latentviral expression. AIDS2004; 18:1101-1108 (Pubitemid 38738509)
115. BoldenJ, PeartM,JohnstoneR.Anticanceractivitiesofhistone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5:769-784.
116. PrinceHM, BishtonMJ, Harrison SJ. Clinical studiesof histone deacetylase inhibitors. Clin Cancer Res 2009; 15:3958-3969.
117. Shehu-Xhilaga M, Rhodes D,Wightman F, Liu HB, Solomon A, Saleh S, et al. The novel histone deacetylase inhibitors meta-cept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells. AIDS 2009; 23:2047-2050.
118. Merck. Zolinza product information 2010.
119. Ellis L, Pan Y, Smyth GK, George DJ, McCormackC, Williams-Truax R, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008; 14:4500-4510.
120. Kim SY, Woo MS, Kim WK, Choi EC, Henson JW, Kim HS. Glial cell-specificregulationof the JCvirus early promoter by histone deacetylase inhibitors. J Virol 2003; 77:3394-3401. (Pubitemid 36297258)
121. Lai MD, Chen CS, Yang CR, Yuan SY, Tsai JJ, Tu CF, et al. An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine. Cancer Gene Ther 2010; 17:203-211.
122. Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006; 130:823-837. (Pubitemid 43374531)
123. Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES, et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor (HDI) therapy: a case series report. Haematologica 2009; 94:1618-1622.
124. Perelson A, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compart-ments during combination therapy. Nature 1997; 387:188-191. (Pubitemid 27209434)
125. North TW, Van Rompay KK, HigginsJ, MatthewsTB, Wadford DA, Pedersen NC, et al. Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.J Virol 2005; 79:7349-7354. (Pubitemid 40756770)
126. Deere JD, Higgins J, Cannavo E, Villalobos A, Adamson L, Fromentin E, et al. Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS. Plos One 2010; 5:e11640.
127. Denton PW, GarciaJV. Novel humanized murine models for HIV research. Curr HIV/AIDS Rep 2009; 6:13-19.
128. Denton PW, Krisko JF, Powell DA, Mathias M, Kwak YT, Martinez-Torres F, et al. Systemic administration of anti-retrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. Plos One 2010; 5:e8829.
129. Rong L, Perelson AS. Modeling latently infected cell acti-vation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol 2009; 5:e1000533.
130. El-Sadr WM, LundgrenJD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of anti-retroviral treatment. N Engl J Med 2006; 355:2283-2296. (Pubitemid 44837777)